{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Related+Adverse+Events",
    "query": {
      "condition": "Immune Related Adverse Events"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 86,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Related+Adverse+Events&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T15:12:40.351Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06211413",
      "title": "Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Atrial Fibrillation",
        "Hypertension",
        "Cardiotoxicity"
      ],
      "interventions": [
        {
          "name": "no intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-02-07",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06211413"
    },
    {
      "nct_id": "NCT05575037",
      "title": "Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nasal Polyps",
        "Asthma, Aspirin-Induced",
        "Aspirin-Exacerbated Respiratory Disease",
        "Aspirin-Sensitive Asthma With Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 17,
      "start_date": "2023-08-01",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05575037"
    },
    {
      "nct_id": "NCT03424733",
      "title": "Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Plegridy",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Tylenol Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Holy Name Medical Center, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-09-25",
      "completion_date": "2020-05-31",
      "has_results": false,
      "last_update_posted_date": "2019-08-15",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Teaneck, New Jersey",
      "locations": [
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03424733"
    },
    {
      "nct_id": "NCT02126020",
      "title": "Topical Infliximab in Autoimmune Eyes With Keratoprosthesis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Toxic Epidermal Necrolysis (Lyell) Syndrome",
        "Mucous Membrane Pemphigoid"
      ],
      "interventions": [
        {
          "name": "topical infliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James Chodosh, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-11",
      "completion_date": "2017-04-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02126020"
    },
    {
      "nct_id": "NCT05598879",
      "title": "Global Cardio Oncology Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Hematologic Malignancy",
        "Immune Checkpoint Inhibitor-Related Myocarditis",
        "Cardiotoxicity",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "anonymized data collection during programmed surveillance clinical follow up",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2022-07-01",
      "completion_date": "2029-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Weston, Florida",
      "locations": [
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05598879"
    },
    {
      "nct_id": "NCT06635954",
      "title": "A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Immunotherapy",
        "PD-1",
        "PD-L1",
        "Immune Checkpoint Therapy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Oxford Biodynamics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2024-05-14",
      "completion_date": "2027-05-14",
      "has_results": false,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 3,
      "location_summary": "Norwich, Connecticut • Dublin, Georgia • Rock Hill, South Carolina",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Dublin",
          "state": "Georgia"
        },
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06635954"
    },
    {
      "nct_id": "NCT04656873",
      "title": "Immuno-Oncology Database and Bioregistry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignancy",
        "Immune System Diseases",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires/Surveys",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2021-05-20",
      "completion_date": "2026-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04656873"
    },
    {
      "nct_id": "NCT05145959",
      "title": "Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Toxic Epidermal Necrolyses",
        "Ocular Surface Disease",
        "Meibomitis",
        "Meibomian Gland Dysfunction",
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Maskin Probe",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-12-01",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-12-06",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145959"
    },
    {
      "nct_id": "NCT04375228",
      "title": "Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune-related Adverse Events",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-09-25",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375228"
    },
    {
      "nct_id": "NCT04571398",
      "title": "A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "ApricityRx mobile application",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Apricity Health, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-11-19",
      "completion_date": "2023-10-15",
      "has_results": false,
      "last_update_posted_date": "2020-10-01",
      "last_synced_at": "2026-07-22T15:12:40.351Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04571398"
    }
  ]
}